Patents Represented by Attorney, Agent or Law Firm Incyte Pharmaceuticals, Inc.
-
Patent number: 5958725Abstract: The invention provides a human DPl homolog (DPlh)) and polynucleotides which identify and encode DPlh. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DPlh.Type: GrantFiled: May 29, 1997Date of Patent: September 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Karl J. Guegler, Purvi Shah, Joanne R. Petithory, Neil C. Corley
-
Patent number: 5958746Abstract: The invention provides human electron transport proteins (NHETP) and polynucleotides which identify and encode NHETP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of NHETP.Type: GrantFiled: October 7, 1997Date of Patent: September 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Olga Bandman, Preeti Lal, Neil C. Corley
-
Patent number: 5958342Abstract: Devices and methods are provided for precise production of arrays of microspots. A pulse jetting device is employed having a capillary of micron dimensions, with a portion of the capillary proximal to the jetting orifice circumferentially surrounded by a piezoelectric transducer. By appropriate design of the capillary, orifice and piezoelectric transducer, droplets can be formed on a surface, separated by as little as 80 microns center-to-center, and having at least about a 15 micron spacing at the border. The subject substrate arrays can be used for providing miniaturized arrays of reagents, such as nucleic acids, for detecting the presence of homologous sequences in a sample.Type: GrantFiled: May 17, 1996Date of Patent: September 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Ronald C. Gamble, Thomas P. Theriault, John Baldeschwieler
-
Patent number: 5958690Abstract: The invention provides a human TSC-22 homolog (HTSCH) and polynucleotides which identify and encode HTSCH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HTSCH.Type: GrantFiled: July 8, 1997Date of Patent: September 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Purvi Shah
-
Patent number: 5958699Abstract: The present invention provides a human tumor-associated Kazal inhibitor (TAKI) and polynucleotides which identify and encode TAKI. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TAKI and a method for producing TAKI. The invention also provides for agonists, antibodies, or antagonists specifically binding TAKI, and their use, in the prevention and treatment of intestinal diseases including cancer. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TAKI for the treatment of diseases associated with the expression of TAKI. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding TAKI.Type: GrantFiled: September 9, 1998Date of Patent: September 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Patent number: 5955312Abstract: The present invention provides a human microtubule-associated protein (hLC3) and the polynucleotides which identify and encode hLC3. The invention also provides genetically engineered expression vectors, host cells, and a method for producing hLC3. The invention also provides hLC3 as well as agonists, antibodies, and antagonists of hLC3, and the use thereof for the prevention and treatment of diseases associated with the expression of hLC3. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding hLC3 for the treatment of diseases associated with the expression of hLC3. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding hLC3.Type: GrantFiled: February 24, 1997Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5955428Abstract: The present invention provides a human metallothionein (HMBP-I) and polynucleotides which identify and encode HMBP-I. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HMBP-I and a method for producing HMBP-I. The invention also provides for agonists, antibodies, or antagonists specifically binding HMBP-I, and their use, in the prevention and treatment of diseases associated with expression of HMBP-I. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HMBP-I for the treatment of diseases associated with the expression of HMBP-I. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HMBP-I.Type: GrantFiled: July 28, 1997Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5955314Abstract: The present invention provides a human regulator of G-protein signaling (HRGS) and polynucleotides which identify and encode HRGS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRGS and a method for producing HRGS. The invention also provides for agonists, antibodies, or antagonists specifically binding HRGS, and their use, in the prevention and treatment of diseases associated with expression of HRGS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRGS for the treatment of diseases associated with the expression of HRGS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRGS.Type: GrantFiled: November 8, 1996Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5955302Abstract: The present invention provides a human dosage compensation-associated protein (HDCAP) and polynucleotides which encode HDCAP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HDCAP and a method for producing HDCAP. The invention also provides for agonists, antibodies, or antagonists specifically binding HDCAP, and their use, in the prevention and treatment of diseases associated with expression of HDCAP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HDCAP for the treatment of diseases associated with the expression of HDCAP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HDCAP.Type: GrantFiled: February 6, 1997Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Surya K. Goli
-
Patent number: 5955301Abstract: The present invention provides a human glutamate-binding protein (HGLUBP) and polynucleotides which identify and encode HGLUBP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGLUBP and a method for producing HGLUBP. The invention also provides for use of HGLUBP and agonists, antibodies, or antagonists specifically binding HGLUBP, in the prevention and treatment of diseases associated with expression of HGLUBP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGLUBP for the treatment of diseases associated with the expression of HGLUBP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGLUBP.Type: GrantFiled: November 14, 1996Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman
-
Patent number: 5955299Abstract: The present invention provides novel human small nuclear ribonucleoprotein (snRNP) Sm proteins (collectively called HSMP) and polynucleotides which identify and encode HSMP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSMP. The invention also provides pharmaceutical compositions containing HSMP or antagonists to HSMP, and in the use of these compositions for the treatment of diseases associated with the expression of HSMP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSMP for the treatment of diseases associated with the expression of HSMP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HSMP or anti-HSMP antibodies which specifically bind to HSMP.Type: GrantFiled: September 27, 1996Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Olga Bandman, Gary B. Zweiger
-
Patent number: 5955284Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.Type: GrantFiled: December 1, 1998Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Dinh Diep, Susan G. Stuart
-
Patent number: 5955305Abstract: The present invention provides a human retinoid binding protein (Hu-RBP) and polynucleotides which identify and encode Hu-RBP. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of Hu-RBP, as well as diagnostic assays.Type: GrantFiled: April 28, 1997Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Joanne R. Petithory
-
Patent number: 5955338Abstract: The invention provides a human phosphatidylinositol 4,5-bisphosphate 5-phosphatase (PBPP) and polynucleotides which identify and encode PBPP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PBPP.Type: GrantFiled: June 27, 1997Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah
-
Patent number: 5955282Abstract: The invention provides human galactosyltransferases (HUGA) and polynucleotides which identify and encode HUGA. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HUGA.Type: GrantFiled: April 3, 1998Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Karl J. Guegler, Neil C. Corley, Purvi Shah, Chandra Patterson
-
Patent number: 5955429Abstract: The present invention provides a novel human apoptosis-associated protein (NHAAP) and polynucleotides which identify and encode NHAAP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHAAP and a method for producing NHAAP. The invention also provides for agonists, antibodies, or antagonists specifically binding NHAAP, and their use, in the prevention and treatment of diseases associated with expression of NHAAP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHAAP for the treatment of diseases associated with the expression of NHAAP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHAAP.Type: GrantFiled: December 15, 1998Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5955283Abstract: The present invention provides a novel human phospholemman-like protein (HPLP) and the polynucleotides which identify and encode HPLP. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HPLP and for a method for producing the protein. The invention also provides pharmaceutical compositions containing HPLP and the use of such compositions for the prevention or treatment of diseases associated with the expression of HPLP. Additionally, the invention provides antisense molecules to HPLP and their use in the treatment of diseases associated with the expression of HPLP. The invention also provides diagnostic assays which utilize polynucleotides which hybridize with naturally occurring sequences encoding HPLP and antibodies which specifically bind to the protein.Type: GrantFiled: May 22, 1998Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 5955303Abstract: The present invention provides a human chemokine receptor-like, protein (NHCR) and polynucleotides which identify and encode NHCR. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of NHCR.Type: GrantFiled: March 6, 1997Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Karl J. Guegler, Muzong Cheng
-
Patent number: 5952209Abstract: The invention provides a human retinol dehydrogenase type II homolog (HRoDH) and polynucleotides which identify and encode HRoDH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HRoDH.Type: GrantFiled: November 18, 1998Date of Patent: September 14, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Neil C. Corley
-
Patent number: 5952181Abstract: The invention provides a human ubiquitin-conjugating enzyme (HUCE-1) and polynucleotides which identify and encode HUCE-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HUCE-1.Type: GrantFiled: January 26, 1999Date of Patent: September 14, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Neil C. Corley